Development and Evaluation of diagnostics and Candidate VACacines for emerging SARS-Coronavirus-2 (DEC-VAC SARS) | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
N/A
Funder
SERB India
Principal Investigator
Dr. StalinRaj Victor
Research Location
India
Lead Research Institution
Indian Institute of Science Education and Research, Thiruvananthapuram
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Investigational vaccines against respiratory viruses

9 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Quantitative Proteomic Analysis Reveals JMJD6 and DNAJB11 as Endogenous Substrates of E3 Ligase RFFL.

Lumazine Synthase Nanoparticles as a Versatile Platform for Multivalent Antigen Presentation and Cross-Protective Coronavirus Vaccines.

Endosomal RFFL ubiquitin ligase regulates mitochondrial morphology by targeting mitofusin 2.

CARPs regulate STUB1 and its pathogenic mutants aggregation kinetics by mono-ubiquitination.

SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells.

Endosomal-associated RFFL facilitates mitochondrial clearance by enhancing PRKN/parkin recruitment to mitochondria.

The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.

SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.

Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.